Mammoth - About the company
Mammoth is a series D company based in Brisbane (United States), founded in 2017 by Trevor Martin, Lucas Harrington, Janice Chen and Jennifer Doudna. It operates as a Provider of molecular diagnostics platform by using CRISPR technology. Mammoth has raised $271M in funding from investors like Redmile Group, Mayfield and Decheng Capital, with a current valuation of $1B. The company has 794 active competitors, including 278 funded and 186 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.
Sectors and market segments that Mammoth operate in
Mammoth serves in the Life Sciences market segments.The primary business model of Mammoth are:Company Details
Mammoth Biosciences offers a CRISPR data platform for diagnostics using Cas12 and Cas13 proteins. The company is creating a new class of diagnostics for industries ranging from oil and gas to agriculture to healthcare. The platform is used to identify disease-causing biomarkers (DNA/RNA).
- Website
- mammoth.bio
- Email ID
- *****@mammothbiosci.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2017
Location
Brisbane, United States
Stage
Series D
Total Funding
$271M in 7 rounds
Latest Funding Round
Post Money Valuation
$1B as on Sep 09, 2021
Investors
Ranked
26th among 794 active competitors
Employee Count
164 as on May 31, 2026
Similar Companies
Sign up to download Mammoth's company profile
Mammoth's funding and investors
Mammoth has raised a total funding of $271M over 7 rounds. Its first funding round was on Sep 14, 2017. Its latest funding round was a Series D round on Sep 09, 2021 for $150M. 9 investors participated in its latest round. Mammoth has 32 institutional investors and 4 angel investors.
Here is the list of recent funding rounds of Mammoth:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 09, 2021 | $150M | Series D | $1B | - | ||
Jan 26, 2021 | Undisclosed | Series C | - | - | - | - |
2020 | $45M | Series C | - | - |
View details of Mammoth's funding rounds and investors
Mammoth's founders and board of directors
Founder? Claim ProfileThe founders of Mammoth are Trevor Martin, Lucas Harrington, Janice Chen and Jennifer Doudna. Trevor Martin is the CEO of Mammoth.
Here are the details of Mammoth's key team members:
- Trevor Martin: Co-Founder & CEO of Mammoth. They are also an angel investor in 4 startups.Contact Info: 1 email address
- Lucas Harrington: Co-Founder & CSO of Mammoth and founder of 1 other company. Contact Info: 2 email addresses
- Janice Chen: Co-founder & CTO of Mammoth.
- Jennifer Doudna: Co-Founder of Mammoth.
View details of Mammoth's Founder profiles and Board Members
Mammoth's employee count trend
Mammoth has 164 employees as of May 26. Here is Mammoth's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Mammoth's Competitors and alternates
Top competitors of Mammoth include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Mammoth, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 77/100 | |
4th | Septerna 2020, San Bruno (United States), Public | Developer of GPCR drug discovery platform for multiple diseases | $250M | 71/100 | |
5th | Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | 71/100 | |
6th | Developer of drugs for treating CNS disorders | - | 69/100 | ||
7th | Passage Bio 2017, Philadelphia (United States), Public | Developer of gene therapies for CNS rare diseases | $226M | 69/100 | |
8th | Pacira 2006, Parsippany Troy Hills (United States), Public | Developer of injectable non-opioid products for post-surgical pain control | $85M | 69/100 | |
9th | Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
10th | AskBio 2001, Durham (United States), Acquired | Developer of AAV technologies for treating genetic and complex disorders | $235M | 68/100 | |
26th | Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 65/100 |
Looking for more details on Mammoth's competitors? Click here to see the top ones
Mammoth's Investments and acquisitions
Mammoth has made no investments or acquisitions yet.
Reports related to Mammoth
Here is the latest report on Mammoth's geography:
News related to Mammoth
Media has covered Mammoth for a total of 3 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.
•
•
•
VedaBio Expands CRISPR Molecular Detection Platform With Mammoth Biosciences’ TechBusiness Wire•Sep 09, 2025•VedaBio, Mammoth
•
Mammoth Biosciences names MB-111 its lead drug candidate and appoints Bob Brown to its board.
Business Wire•May 05, 2025•Mammoth
•
•
Regeneron and Mammoth Biosciences to CollaborateEuropean Pharmaceutical Manufacturer•Apr 26, 2024•Regeneron Pharmaceuticals, Mammoth
•
Regeneron and Mammoth team up to develop gene editing therapiesPharmaceutical Technology•Apr 26, 2024•Regeneron Pharmaceuticals, Mammoth
•
Regeneron & Mammoth Partner on CRISPR TherapiesContract Pharma•Apr 25, 2024•Regeneron Pharmaceuticals, Mammoth
•
Peninsula biotech co-founded by Jennifer Doudna lands CRISPR gene-editing pact with RegeneronThe Business Journals•Apr 25, 2024•Regeneron Pharmaceuticals, Mammoth
•
Are you a Founder ?
FAQs about Mammoth
Explore our recently published companies
- Alphainstruments - Unfunded company
- BauGPT - Munich based, 2022 founded, Funding Raised company
- Dryft - San Francisco based, 2024 founded, Seed company
- Quimas - Maipu based, 2003 founded, Unfunded company
- Process Tech - Salt Lake City based, 1996 founded, Unfunded company
- YTM - Raipur based, 2015 founded, Unfunded company
